NewsBenzinga셉테르나, 그레이브스병 및 TED 치료제 개발 후보물질로 SEP-204 선정 발표···2026년 ATA 연례회의 포스터 발표에 앞서 초기 전임상 데이터 공개 셉테르나, 그레이브스병 및 TED 치료제 개발 후보물질로 SEP-204 선정 발표···2026년 ATA 연례회의 포스터 발표에 앞서 초기 전임상 데이터 공개 Benzinga 2026.11.04 13:04 (GMT+0) Open on Benzinga Other news NRX Pharmaceuticals Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $1.159M Miss $1.300M Estimate HUYA Q3 Adj. EPS $0.03 Up From $0.02 YoY, Sales $261.441M Up From $237.147M YoY Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’ Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk Top Wall Street Forecasters Revamp Energizer Expectations Ahead Of Q4 Earnings
Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’
Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL
Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk